HomeCompareAKYA vs NOBL

AKYA vs NOBL: Dividend Comparison 2026

AKYA yields 155.04% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AKYA wins by $29.56M in total portfolio value
10 years
AKYA
AKYA
● Live price
155.04%
Share price
$1.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.59M
Annual income
$13,040,704.30
Full AKYA calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — AKYA vs NOBL

📍 AKYA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAKYANOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AKYA + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AKYA pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AKYA
Annual income on $10K today (after 15% tax)
$13,178.29/yr
After 10yr DRIP, annual income (after tax)
$11,084,598.66/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, AKYA beats the other by $11,084,386.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AKYA + NOBL for your $10,000?

AKYA: 50%NOBL: 50%
100% NOBL50/50100% AKYA
Portfolio after 10yr
$14.80M
Annual income
$6,520,477.04/yr
Blended yield
44.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AKYA right now

AKYA
Analyst Ratings
2
Buy
7
Hold
Consensus: Hold
Price Target
$4.98
+286.0% upside vs current
Range: $2.40 — $7.50
Altman Z
-4.2
Piotroski
4/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AKYA buys
0
NOBL buys
0
No recent congressional trades found for AKYA or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAKYANOBL
Forward yield155.04%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$29.59M$22.9K
Annual income after 10y$13,040,704.30$249.78
Total dividends collected$27.44M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: AKYA vs NOBL ($10,000, DRIP)

YearAKYA PortfolioAKYA Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$26,204$15,503.88$10,917$217.08+$15.3KAKYA
2$66,007$37,968.38$11,903$221.48+$54.1KAKYA
3$160,011$89,383.96$12,962$225.68+$147.0KAKYA
4$373,718$202,506.35$14,099$229.68+$359.6KAKYA
5$841,906$442,027.47$15,319$233.49+$826.6KAKYA
6$1,831,486$930,646.81$16,628$237.10+$1.81MAKYA
7$3,851,778$1,892,087.52$18,033$240.53+$3.83MAKYA
8$7,840,307$3,718,904.61$19,539$243.78+$7.82MAKYA
9$15,463,748$7,074,619.86$21,154$246.86+$15.44MAKYA
10$29,586,915$13,040,704.30$22,884$249.78+$29.56MAKYA

AKYA vs NOBL: Complete Analysis 2026

AKYAStock

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Full AKYA Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this AKYA vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AKYA vs SCHDAKYA vs JEPIAKYA vs OAKYA vs KOAKYA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.